Advertisement

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study

Published:August 31, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.08.006

      Highlights

      • Phase I study of sequential extended field ChemoRT and combination chemotherapy
      • Phase I study for primary therapy of para-aortic node positive cervical cancer
      • Adjuvant chemotherapy in the primary management of advanced cervical cancer
      • Safety and feasibility of paclitaxel and carboplatin after extended field RT

      Abstract

      Background

      Chemo-radiation (chemoRT) has improved the overall survival for locally advanced cervical cancer (LACC) though women whose disease involves the para-aortic nodes (PAN) experience recurrence rates and worse survival outcomes compared to those without PAN involvement. This Phase I study determined if additional cycles of systemic chemotherapy could be safely added to extended field chemoRT in this population of patients.

      Methods

      Women with LACC and documented positive PAN were eligible for treatment. All women were treated with extended field radiation and brachytherapy and concurrent cisplatin 40 mg/m2 weekly for six weeks. Four to six weeks after completion of chemoRT, patients were treated with four cycles of paclitaxel 135 mg/m2 and escalating doses of carboplatin (Dose Level (DL) 1 = AUC 4, DL2 = AUC 5).

      Results

      Eleven women were entered on study and 9 were evaluable for dose limiting toxicities (DLT). Two women (1 in each of 2 DLs) did not complete chemoRT and so were not evaluable for DLT. Three women completed all 10 cycles at DL 1 with no DLTs. Six women were then treated at DL 2. For the 10 patients evaluable for response, the ORR was 60% (CR + PR). PFS and OS at 12 months were 60% and 90%, respectively. The predominant grade 3 or 4 acute toxicities were hematologic. There were no grade 5 events.

      Conclusion

      Extended field chemoRT followed by paclitaxel 135 mg/m2 and carboplatin AUC 5 is feasible in women with LACC and positive PAN.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA Cancer J. Clin. 2017; 67: 7-30
        • Leblanc E.
        • Gaulthier H.
        • Querleu D.
        • et al.
        Accuracy of 18-fluoro-2-deoxy-d-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
        Ann. Surg. Oncol. 2011; 18: 2302-2309
        • Kim H.J.
        • Ha S.W.
        • Wu H.G.
        Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy.
        Gynecol. Oncol. 2009; 20: 227-231
        • Varia M.A.
        • Bundy B.N.
        • Deppe G.
        • et al.
        Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
        Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 1015-1023
        • Eifel P.J.
        • Winter K.
        • Morris M.
        • et al.
        Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
        J. Clin. Oncol. 2004; 22: 872-880
        • Husseinzadeh N.
        • Shrake P.
        • DeEulis T.
        • Rowley K.
        • Aron B.
        Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study.
        Gynecol. Oncol. 1994; 52: 326-331
        • Kim Y.S.
        • Kim J.H.
        • Ahn S.D.
        • et al.
        High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
        Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 1522-1528
        • Small Jr., W.
        • Winter K.
        • Levenback C.
        • et al.
        Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.
        Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 1081-1087
        • Duenas-Gonzalez A.
        • Zarba J.J.
        • Patel F.
        • et al.
        Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
        J. Clin. Oncol. 2011; 29: 1678-1685
        • Walker J.L.
        • Morrison A.
        • DiSilvestro P.
        • et al.
        A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2009; 112: 78-84
        • Moore D.H.
        • Blessing J.A.
        • McQuellon R.P.
        • et al.
        Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
        J. Clin. Oncol. 2004; 22: 3113-3119
        • Long 3rd, H.J.
        • Bundy B.N.
        • Grendys Jr., E.C.
        • et al.
        Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
        J. Clin. Oncol. 2005; 23: 4626-4633
        • Monk B.J.
        • Sill M.W.
        • McMeekin D.S.
        • et al.
        Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2009; 27: 4649-4655
        • Tewari K.S.
        • Sill M.W.
        • Long 3rd, H.J.
        • et al.
        Improved survival with bevacizumab in advanced cervical cancer.
        N. Engl. J. Med. 2014; 370: 734-743
        • Pectasides D.
        • Fountzilas G.
        • Papaxoinis G.
        • et al.
        Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
        Int. J. Gynecol. Cancer. 2009; 19: 777-781
        • Kitagawa R.
        • Katsumata N.
        • Shibata T.
        • et al.
        Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized Phase III Trial JCOG0505.
        J. Clin. Oncol. 2015; 33: 2129-2135
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur. J. Cancer. Jan 2009; 45: 228-247
        • Frenel J.S.
        • Le Tourneau C.
        • O'Neil B.
        • et al.
        Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial.
        J. Clin. Oncol. 2017; 35: 4035-4041